Genomind Names Scientific Advisory Board

Genomind Names Scientific Advisory Board

NORFOLK, VA – September 29, 2010 – Genomind, LLC, a company specializing in neuropsychiatric personalized medicine, announced today the formation of its inaugural Scientific Advisory Board. The Scientific Advisory Board (SAB) consists of international thought leaders with in depth clinical and research experience in neuropsychiatric medicine.

The Board will initially be comprised of Scott T. Aaronson, MD, Director of Clinical Research at Sheppard Pratt, Clinical Assistant Professor of Psychiatry at the University of Maryland School of Medicine and Distinguished Fellow of the American Psychiatric Association; Maurizio Fava, MD, Executive Vice Chair, Department of Psychiatry, at the Massachusetts General Hospital and Slater Family Professor of Psychiatry, Harvard Medical School; Roy H. Perlis, MD, Medical Director of the Bipolar Clinical and Research Program and Director, Psychiatric Pharmacogenomics Program, at the Massachusetts General Hospital; and Stephen Stahl, MD, Adjunct Professor of Psychiatry at the University of California San Diego and Chairman of the Neuroscience Education Institute.

“I am pleased to welcome these distinguished and well respected individuals to the Genomind Scientific Advisory Board,” said Ronald I. Dozoretz, MD, Chairman and CEO of Genomind, LLC. “They bring a great wealth of knowledge and clinical experience to the company. Their contributions will further strengthen the company’s mission of bringing personalized medicine to psychiatry and to patients in need.”

Scott T. Aaronson, MD

Dr. Aaronson is a thought leader in the areas of biological psychiatry, diagnosis and the integration of somatic and psychological therapies. He is a Clinical Assistant Professor of Psychiatry at the University of Maryland School of Medicine and Distinguished Fellow of the American Psychiatric Association.

Dr. Aaronson is the Associate Medical Director, at The Retreat at Sheppard Pratt, a premiere, self funded psychiatric setting. In addition to this role, Dr. Aaronson is also the Director of Clinical Research at Sheppard Pratt and is the principal investigator for multiple studies on the development of novel therapies for mood, anxiety and psychotic disorders. Dr. Aaronson has nearly twenty years of experience treating patients with affective disorders at the New England Psychiatric Group, a clinic he founded, and at McLean Hospital; Newton-Wellesley Hospital; and Saint Anne’s Hospital. He has also taught psychiatry at Harvard Medical School. He specializes in treatment-resistant affective disorders.

He is a valued speaker and educator and frequently lectures on varied aspects of mood disorders both regionally and nationally, including: integration of biological and psychotherapies, complex mood disorders, psychoeducation and development of new therapies. He also provides diagnostic and psychopharmacological consultation. In 1981, Dr. Aaronson was the recipient of the Sirgay Sanger Award for excellence in psychiatric research. Dr. Aaronson received his MD from Harvard Medical School and his B.A. from Columbia University.

Maurizio Fava, MD

Dr. Fava is Executive Vice Chair of the Department of Psychiatry at the Massachusetts General Hospital. He also serves as Executive Director, Clinical Trials Network and Institute (CTNI); Director, Depression Clinical and Research Program (DCRP) at the MGH, and is the Slater Family Professor of Psychiatry, Harvard Medical School.

Dr. Fava has extensive research experience in conducting and completing studies in depressed populations. Under his direction since 1990, the DCRP has become one of the most highly regarded depression programs in the country, conducting research projects in a variety of areas, including pharmacotherapy of resistant depression, neuroimaging, genetics, neurophysiology, neuroendocrinology, novel pharmacotherapies, alternative medicine, and psychotherapy.

Dr. Fava has been Principal Investigator of more than 40 NIMH and industry-supported clinical trials in unipolar depression. Dr. Fava’s clinical and consulting practice specializes in treatment resistant depression, and he consults extensively with colleagues on management of this condition. Dr. Fava has authored or co-authored more than 450 original articles published in medical journals with international circulation. He has also edited six books, and published more than 50 chapters and over 500 abstracts. Dr. Fava is a well-known national and international speaker, having given more than 400 presentations
during his career in psychiatry.

Dr. Fava obtained his medical degree from the University of Padova School of Medicine and completed residency training in endocrinology at the same university. He also completed a residency in psychiatry at the Massachusetts General Hospital.

Roy H. Perlis, MD MSc

Dr. Perlis is the Medical Director of the Bipolar Clinic and Research Program and Director of Pharmacogenomics Research in the Department of Psychiatry at the Massachusetts General Hospital, and Associate Professor at Harvard Medical School.

Dr. Perlis’ clinical work and research is focused on difficult-to-treat or treatment resistant mood disorders, including major depressive disorder and bipolar disorder. He is the author of more than 100 peer-reviewed research publications as well as numerous book chapters and reviews. Current research efforts include identifying predictors of treatment response and identifying and studying novel treatments for mood disorders.

A graduate of Brown University and Harvard Medical School, Dr. Perlis completed his residency, chief residency, and clinical/research fellowship at the Massachusetts General Hospital before joining the faculty.

Stephen M. Stahl, MD, PhD

Dr. Stahl is Adjunct Professor of Psychiatry at the University of California San Diego and Honorary Visiting Senior Fellow, University of Cambridge, UK.
Dr. Stahl has held faculty positions at Stanford University, the University of California at Los Angeles, the Institute of Psychiatry London, and the Institute of Neurology London. Dr. Stahl was also Executive Director of Clinical Neurosciences at the Merck Neuroscience Research Center in the UK for several years. Dr. Stahl’s major interests are dedicated to producing and disseminating educational information about diseases and their treatment in psychiatry and neurology, with a special emphasis on multimedia, the Internet, and teaching how to teach.

Dr. Stahl has conducted numerous research projects during his career awarded by NIMH, the Veterans Administration, and the pharmaceutical industry. Author of over 425 articles and more than 1500 scientific presentations and abstracts, Dr. Stahl is an internationally recognized clinician, researcher, and teacher in psychiatry with subspecialty expertise in psychopharmacology. Dr. Stahl has edited five books and written 25 more, including the best-selling textbook Stahl’s Essential Psychopharmacology, now in its third edition, and the best selling clinical manual, Essential Psychopharmacology Prescriber’s Guide, also in its third edition.

Dr. Stahl received his undergraduate and medical degrees from Northwestern University in Chicago and his Ph.D. in pharmacology and physiology from the University of Chicago. He has trained in three specialties: internal medicine at the University of Chicago, neurology at the University of California in San Francisco, and psychiatry at Stanford. He is board certified in psychiatry.

About Genomind, LLC

Genomind, LLC is a company specializing in neuropsychiatric personalized medicine and was formed to facilitate the adoption of Personalized Medicine into psychiatry by assisting physicians in the selection of appropriate medicine based on genetic information. Genomind was founded by Ronald I. Dozoretz, MD, in 2009, and the company is advised by a group of renowned experts in the fields of human genetics and neuropsychiatric medicine. More information is available at:

For more information, contact:

Adam Shapiro

Amy Pressman
Marketing Manager, Genomind

} ); } ( jQuery ) );